duit Pharmaceuticals (CDT)

Search documents
duit Pharmaceuticals (CDT) - 2024 Q2 - Quarterly Report
2024-08-12 21:29
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT T O SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41245 CONDUIT PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) | --- | --- | |----------------------- ...
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
GlobeNewswire News Room· 2024-08-12 11:00
Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656 AZD1656, a HK-4 glucokinase activator initially developed by AstraZeneca for diabetes, is now being repurposed by Conduit for autoimmune disorders, leveraging its established safety profile and targeted immune-modulating effects SAN DIEGO and LONDON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Condu ...
Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?
Investor Place· 2024-07-16 12:12
Core Viewpoint - Conduit Pharmaceuticals has received a new patent for its HK-4 Glucokinase Activator, which targets autoimmune diseases, leading to a significant increase in its stock price [2][7]. Company Developments - The company has secured an Australian patent for its lead asset, which is expected to enhance its intellectual property portfolio and future out-licensing opportunities [2][7]. - Conduit Pharmaceuticals plans to pursue similar patents in other regions, including the U.S., Europe, and Japan, utilizing the Patent Prosecution Highway (PPHH) [3]. Market Reaction - Following the patent approval, Conduit Pharmaceuticals' stock (CDT) experienced a trading surge, with over 41.7 million shares traded, significantly higher than its average daily volume of approximately 317,000 shares [7]. - As of Tuesday morning, CDT stock rose by 73%, although it had previously declined by 94.9% year-to-date before this news [8].
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Newsfilter· 2024-07-16 11:30
The Company is enrolled to participate in the Patent Prosecution Highway (PPH), a program to fast-track patent examination in major jurisdictions including the U.S., Europe and Japan. Since IP Australia has allowed patent application 2022384750, Conduit believes it is more likely to receive subsequent approvals in other markets. Patents in these major countries are the most sought after and valuable patents for marketed drug products, providing up to 20 years of patent protection. Conduit Pharmaceuticals (N ...
CDT Environmental Technology Investment Holdings Limited Announces Strategic Partnership with Leading Pipeline Inspection and Data Services Provider in Fujian
GlobeNewswire News Room· 2024-06-27 12:00
SHENZHEN, China, June 27, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) ("CDT"), a leading provider of waste treatment systems and services throughout China, announces the signing of a strategic cooperation framework agreement with a local high-tech company in Fujian Province. The collaboration leverages the complementary strengths of both parties, with CDT contributing its government relations, brand advantages, and expertise in waste treatment solutions, ...
CDT Environmental Technology Investment Holdings Limited Announces Strategic Cooperation Agreement with Subsidiary of Chinese State-Owned Construction Group
GlobeNewswire News Room· 2024-06-18 12:30
SHENZHEN, China, June 18, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) ("CDT"), a leading provider of waste treatment systems and services throughout China, announces the signing of a strategic cooperation agreement with a subsidiary of a large stateowned construction group in China. The parent company of the state-owned construction group is among the top 40 in ENR's 2023 ranking of the world's largest contractors. Under the terms of the agreement, the tw ...
A Presidio Property Trust Major Investment To Be Part of Russell 2000®
Newsfilter· 2024-05-29 20:21
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ: SQFT; SQFTP; SQFTW) ("Presidio" or the "Company"), an internally managed, diversified real estate investment trust ("REIT"), has announced that Conduit Pharmaceuticals Inc. (NASDAQ: CDT, CDTTW) ("Conduit"), of which the Company owns approximately 6.3%, is expected to be added to the Russell 2000 Index effective at the open of US equity markets on Monday, July 1, 2024, as part of the annual reconstitution of the Russell stock ...
CDT Environmental Technology Investment Holdings Limited Establishes Partnership with Fortune 500 Company's Subsidiary to Jointly Bid for Large-Scale Sewage Treatment Facility in Hengqin, China
globenewswire.com· 2024-05-22 12:01
CDT, headquartered in Shenzhen, China, is a leading national player in China's waste treatment sector that designs, develops, manufactures, sells, installs, operates and maintains sewage treatment systems and provides sewage treatment services in China, and is dedicated to promoting sustainable development through innovative solutions. Founded by pioneers in waste treatment, CDT aims to advance next-generation technologies that directly address environmental challenges and promote sustainable solutions. CDT ...
CDT Environmental Technology Investment Holdings Limited Files Annual Report on Form 20-F
globenewswire.com· 2024-05-21 00:00
Announced three new patents that feature new AI-powered intelligent waste-sorting technologies Subsequent to 2023 year-end: "Following our IPO just a few weeks ago, we are pleased to report our third consecutive year of growth at both the top- and bottom-lines, with fundamentals continuing to trend well for our shareholders," remarked Yunwu Li, Chief Executive Officer of CDT. "The market demand continues to support the growth of our business, and indeed, we are proud of the consistent progress we have made ...
duit Pharmaceuticals (CDT) - 2024 Q1 - Quarterly Report
2024-05-14 20:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended March 31, 2024 For the transition period from to | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------| | Delaware \n(State or other jurisdiction of incorporation or organization) \n4995 Murphy Canyon Road, Suit ...